Literature DB >> 6323053

"Nonspecific" increases in plasma immunoreactive calcitonin in healthy individuals: discrimination from medullary thyroid carcinoma by a new extraction technique.

J J Body, H Heath.   

Abstract

Occasional seemingly healthy individuals have above-normal concentrations of calcitonin-like immunoreactivity in their plasma, which can lead to mistaken diagnosis of thyroidal or other cancer. We measured immunoreactive calcitonin (CT) before and after extracting the plasma on columns of silica (to improve sensitivity and specificity of the assay for monomeric calcitonin) in five "healthy high-CT" men (I), five patients with known medullary thyroid carcinoma (II), and 30 normal controls (III). Median (and range) values (pg/mL = ng/L) for whole-plasma immunoreactive CT in these groups were, respectively, 379 (157-526), 429 (174-563), and 33 (less than 25-92). Dose-dilution curves for plasma samples from group I did not parallel the standard curve, in contrast to samples from the other two groups. Values for extractable CT from plasma from groups I and III, however, were indistinguishable, but remained significantly increased in group II. Infusions of Ca, 2 mg/kg body wt. in 5 min, produced the expected (normal) increases in extractable CT in group I. The occasional factor (or factors) in plasma of healthy persons that interferes in assays for CT is eliminated by the silica extraction method, and in this way such cases can be distinguished from cases of medullary thyroid carcinoma.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6323053

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  5 in total

1.  Immunoreactive "calcitonin-like" material in heroin addicts: varying reactivity with different antibodies.

Authors:  F Tagliaro; R Dorizzi; S Ghielmi; E Comberti; P Alverà; E Manzato; M Marigo
Journal:  Int J Legal Med       Date:  1992       Impact factor: 2.686

2.  Calcitonin and bone mass status in congenital hypothyroidism.

Authors:  N Demeester-Mirkine; P Bergmann; J J Body; J Corvilain
Journal:  Calcif Tissue Int       Date:  1990-04       Impact factor: 4.333

3.  A case of spurious hypercalcitoninemia: a cautionary tale on the use of plasma calcitonin assays in the screening of patients with thyroid nodules for neoplasia.

Authors:  G I Uwaifo; A T Remaley; M Stene; J C Reynolds; P M Yen; R H Snider; K L Becker; N J Sarlis
Journal:  J Endocrinol Invest       Date:  2001-05       Impact factor: 4.256

4.  Calcitonin metabolism in senile (type II) osteoporosis.

Authors:  J Y Reginster; R Deroisy; M Bruwier; P Franchimont
Journal:  Osteoporos Int       Date:  1992-05       Impact factor: 4.507

5.  Bone loss during gonadotropin-releasing hormone agonist treatment in girls with true precocious puberty is not due to an impairment of calcitonin secretion.

Authors:  G Saggese; S Bertelloni; G I Baroncelli; D Pardi; L Cinquanta
Journal:  J Endocrinol Invest       Date:  1991-03       Impact factor: 4.256

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.